Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Iron oxide nanoparticles for treatment and diagnosis of chronic inflammatory diseases: A systematic review
Publication Year: 2024 Source: Wiley Interdiscip Rev Nanomed Nanobiotechnol PMID: 38725229
No Abstract
Inflammatory Bowel Disease and Its Association With Perinuclear Antineutrophil Cytoplasmic Antibodies: A Systematic Review
Publication Year: 2024 Source: Cureus PMID: 38725759 DOI: 10.7759/cureus.57872
An idiopathic condition known as inflammatory bowel disease (IBD) is characterized by a dysregulated immune response to the intestinal flora of the host. It falls into one of two primary categories: ulcerative colitis or Crohn's disease. A wide range of disorders, both clinically and genetically, can cause IBD. The purpose …
Calycosin prevents NLRP3-induced gut fibrosis by regulating IL-33/ST2 axis
Publication Year: 2024 Source: Heliyon PMID: 38726105 DOI: 10.1016/j.heliyon.2024.e30240
Intestinal interstitial fibrosis is a core event of inflammatory bowel disease (IBD) development. Calycosin has been recognized to carry various therapeutic bioactivities. However, the role of calycosin in intestinal interstitial fibrosis remains to be illustrated. This aim of this study was to explore the effects of calycosin on intestinal interstitial …
Take vedolizumab home: transition from intravenous to subcutaneous treatment
Publication Year: 2024 Source: Ther Adv Chronic Dis PMID: 38726235 DOI: 10.1177/20406223241247648
In 2020, the European Medicines Agency approved subcutaneous (SC) vedolizumab (VDZ) for the maintenance treatment of adult patients with moderate to severe inflammatory bowel disease (IBD). This article reviews the efficacy, safety, persistence, pharmacology, patient satisfaction, and economic implications of transitioning to SC VDZ treatment and explores whether SC formulations …
[The perspective of the expert gastroenterologist in inflammatory bowel disease]
Publication Year: 2024 Source: Nutr Hosp PMID: 38726602
No Abstract
[Nursing in the approach to inflammatory bowel disease]
Publication Year: 2024 Source: Nutr Hosp PMID: 38726618
No Abstract
Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD
Publication Year: 2024 Source: Aliment Pharmacol Ther PMID: 38726810 DOI: 10.1111/apt.18027
No Abstract
Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD-Authors' reply
Publication Year: 2024 Source: Aliment Pharmacol Ther PMID: 38726864 DOI: 10.1111/apt.18031
No Abstract
Re-resection Rates and Disease Recurrence in Crohn's Disease: A Population-based Study Using Individual-level Patient Data
Publication Year: 2024 Source: J Crohns Colitis PMID: 38727089
No Abstract
Il-6 and MSH3 in colorectal carcinoma: Expression, relationship, and prognostic significance in 171 colorectal carcinoma cases
Publication Year: 2024 Source: Indian J Pathol Microbiol PMID: 38727512
No Abstract
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide